GSK Acquires Syndivia's Prostate Cancer ADC
GSK has acquired the rights to Syndivia's preclinical antibody drug conjugate (ADC) for prostate cancer treatment, despite having its own ADC in development for the same condition.
This move further fuels the industry's interest in the promising anti-tumour modality.
The gold standard of business intelligence.
GSK's acquisition is valued at £268m, demonstrating the company's commitment to the modality.
Author's summary: GSK buys Syndivia's ADC for £268m.